Operaciones DiaMedica Therapeutics Inc. - DMAC CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Diferencial | 0.0978 | ||||||||
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.024068% | ||||||||
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.001846% | ||||||||
Horario tarifa nocturna | 21:00 (UTC) | ||||||||
Cantidad comercializada mínima | 1 | ||||||||
Divisa | USD | ||||||||
Margen | 20% | ||||||||
Mercado de valores | United States of America | ||||||||
Comisión por operación | 0% |
*Information provided by Capital.com
Cierre previo* | 1.438 |
Abrir* | 1.3687 |
Cambio de 1 año* | -50.23% |
Rango del día* | 1.3686 - 1.5261 |
Rango de 52 semanas | 1.12-2.81 |
Volumen medio (10 días) | 24.25K |
Volumen medio (3 meses) | 788.43K |
Capitalización de mercado | 42.04M |
Ratio P/E | -100.00K |
Acciones en circulación | 26.44M |
Ingresos | N/A |
EPS | -0.50 |
Dividendo (Rendimiento %) | N/A |
Beta | 1.76 |
Próxima fecha de resultados | Mar 28, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Cierre | Change | Change (%) | Apertura | High | Low |
---|---|---|---|---|---|---|
Mar 24, 2023 | 1.5261 | 0.1576 | 11.52% | 1.3685 | 1.5261 | 1.3684 |
Mar 23, 2023 | 1.4380 | -0.1068 | -6.91% | 1.5448 | 1.5751 | 1.4380 |
Mar 22, 2023 | 1.5458 | -0.0479 | -3.01% | 1.5937 | 1.6633 | 1.5454 |
Mar 21, 2023 | 1.6729 | -0.0391 | -2.28% | 1.7120 | 1.7122 | 1.5843 |
Mar 20, 2023 | 1.6925 | -0.0382 | -2.21% | 1.7307 | 1.7314 | 1.6529 |
Mar 17, 2023 | 1.7316 | -0.0188 | -1.07% | 1.7504 | 1.7505 | 1.7010 |
Mar 16, 2023 | 1.8296 | 0.0891 | 5.12% | 1.7405 | 1.8394 | 1.7405 |
Mar 15, 2023 | 1.6923 | -0.0383 | -2.21% | 1.7306 | 1.7416 | 1.6820 |
Mar 14, 2023 | 1.7805 | 0.0878 | 5.19% | 1.6927 | 1.8297 | 1.6422 |
Mar 13, 2023 | 1.6922 | 0.1276 | 8.16% | 1.5646 | 1.7221 | 1.5646 |
Mar 10, 2023 | 1.6531 | -0.0182 | -1.09% | 1.6713 | 1.7019 | 1.5645 |
Mar 9, 2023 | 1.6923 | 0.0502 | 3.06% | 1.6421 | 1.7707 | 1.6421 |
Mar 8, 2023 | 1.7709 | 0.0994 | 5.95% | 1.6715 | 1.7906 | 1.6715 |
Mar 7, 2023 | 1.7219 | 0.0798 | 4.86% | 1.6421 | 1.7221 | 1.6421 |
Mar 6, 2023 | 1.7020 | -0.0188 | -1.09% | 1.7208 | 1.7612 | 1.6723 |
Mar 3, 2023 | 1.7316 | 0.0790 | 4.78% | 1.6526 | 1.7514 | 1.6526 |
Mar 2, 2023 | 1.7414 | 0.0300 | 1.75% | 1.7114 | 1.7612 | 1.7114 |
Mar 1, 2023 | 1.7315 | -0.0294 | -1.67% | 1.7609 | 1.7609 | 1.6428 |
Feb 28, 2023 | 1.6923 | 0.0502 | 3.06% | 1.6421 | 1.7416 | 1.6421 |
Feb 27, 2023 | 1.6535 | 0.0099 | 0.60% | 1.6436 | 1.7024 | 1.5842 |
DiaMedica Therapeutics Inc. Events
Hora (UTC) (UTC) | País | Evento |
---|---|---|
No events scheduled |
- Anual
- Trimestral
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Ingresos totales | 0 | 0 | 0 | 0.5 | 0 |
Gastos totales de explotación | 13.646 | 12.699 | 11.593 | 7.261 | 4.519 |
Gastos de venta/general/administración Gastos, total | 4.881 | 4.389 | 3.693 | 2.739 | 1.313 |
Investigación y desarrollo | 8.765 | 8.31 | 7.9 | 4.522 | 3.206 |
Depreciation / Amortization | |||||
Ingresos de explotación | -13.646 | -12.699 | -11.593 | -6.761 | -4.519 |
Ingresos por intereses (gastos), netos No operativos | 0 | -0.039 | 0.009 | ||
Otros, netos | 0.082 | 0.434 | 0.975 | 1.146 | 0.25 |
Ingresos netos antes de impuestos | -13.564 | -12.265 | -10.618 | -5.654 | -4.26 |
Ingresos netos después de impuestos | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
Beneficio neto antes de partidas extra. Elementos | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
Ingresos netos | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
Beneficio neto diluido | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
Promedio ponderado de acciones diluidas | 20.7734 | 15.6803 | 11.9877 | 7.74352 | 5.93579 |
BPA diluido sin partidas extraordinarias | -0.6543 | -0.78391 | -0.88833 | -0.74049 | -0.71768 |
BPA normalizado diluido | -0.6543 | -0.78391 | -0.88833 | -0.74049 | -0.71768 |
Ingresos | 0 | 0.5 | 0 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Ingresos totales | 0 | 0 | 0 | 0 | 0 |
Gastos totales de explotación | 3.536 | 3.246 | 3.416 | 3.365 | 3.619 |
Gastos de venta/general/administración Gastos, total | 1.562 | 1.375 | 1.084 | 1.209 | 1.213 |
Investigación y desarrollo | 1.974 | 1.871 | 2.332 | 2.156 | 2.406 |
Ingresos de explotación | -3.536 | -3.246 | -3.416 | -3.365 | -3.619 |
Otros, netos | 0.035 | 0.007 | -0.027 | 0.098 | 0.004 |
Ingresos netos antes de impuestos | -3.501 | -3.239 | -3.443 | -3.267 | -3.615 |
Ingresos netos después de impuestos | -3.508 | -3.246 | -3.45 | -3.274 | -3.622 |
Beneficio neto antes de partidas extra. Elementos | -3.508 | -3.246 | -3.45 | -3.274 | -3.622 |
Ingresos netos | -3.508 | -3.246 | -3.45 | -3.274 | -3.622 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -3.508 | -3.246 | -3.45 | -3.274 | -3.622 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -3.508 | -3.246 | -3.45 | -3.274 | -3.622 |
Beneficio neto diluido | -3.508 | -3.246 | -3.45 | -3.274 | -3.622 |
Promedio ponderado de acciones diluidas | 26.4431 | 26.5021 | 19.0357 | 18.7862 | 18.7667 |
BPA diluido sin partidas extraordinarias | -0.13266 | -0.12248 | -0.18124 | -0.17428 | -0.193 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
BPA normalizado diluido | -0.13266 | -0.12248 | -0.18124 | -0.17428 | -0.193 |
- Anual
- Trimestral
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Activo Corriente | 45.439 | 27.921 | 8.836 | 17.972 | 1.494 |
Efectivo e inversiones a corto plazo | 45.112 | 27.507 | 7.878 | 16.823 | 1.353 |
Cash | 4.707 | 7.409 | 3.883 | 16.823 | 1.353 |
Total deudores, neto | 0.13 | 0.34 | 0.823 | 0.78 | 0.08 |
Prepaid Expenses | 0.084 | 0.064 | 0.047 | 0.369 | 0.061 |
Total Assets | 45.551 | 28.095 | 9.053 | 18.339 | 1.802 |
Property/Plant/Equipment, Total - Net | 0.112 | 0.174 | 0.217 | 0.096 | 0.037 |
Property/Plant/Equipment, Total - Gross | 0.179 | 0.231 | 0.26 | ||
Accumulated Depreciation, Total | -0.067 | -0.057 | -0.043 | ||
Total Current Liabilities | 1.524 | 2.028 | 1.318 | 1.296 | 1.003 |
Accounts Payable | 0.509 | 1.099 | 0.182 | ||
Accrued Expenses | 1.011 | 0.923 | 1.13 | ||
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0 | 0.084 | |||
Total Liabilities | 1.527 | 2.081 | 1.436 | 1.314 | 1.003 |
Total Long Term Debt | 0.003 | 0.007 | 0.013 | 0.018 | 0 |
Other Liabilities, Total | 0 | 0.046 | 0.105 | ||
Total Equity | 44.024 | 26.014 | 7.617 | 17.025 | 0.799 |
Common Stock | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 126.576 | 94.925 | 64.232 | 62.993 | 41.033 |
Retained Earnings (Accumulated Deficit) | -82.501 | -68.909 | -56.617 | -45.968 | -40.234 |
Other Equity, Total | -0.051 | -0.002 | 0.002 | ||
Total Liabilities & Shareholders’ Equity | 45.551 | 28.095 | 9.053 | 18.339 | 1.802 |
Total Common Shares Outstanding | 26.4431 | 18.7462 | 12.0069 | 11.9569 | 6.37066 |
Accounts Receivable - Trade, Net | 0.13 | 0.78 | 0.08 | ||
Other Long Term Assets, Total | 0 | 0.271 | 0.271 | ||
Payable/Accrued | 1.291 | 0.919 | |||
Current Port. of LT Debt/Capital Leases | 0.004 | 0.006 | 0.006 | 0.005 | 0 |
Capital Lease Obligations | 0.003 | 0.007 | 0.013 | 0.018 | 0 |
Inversiones a corto plazo | 40.405 | 20.098 | 3.995 | ||
Other Current Assets, Total | 0.113 | 0.01 | 0.088 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Activo Corriente | 42.111 | 45.439 | 48.537 | 21.629 | 24.195 |
Efectivo e inversiones a corto plazo | 41.047 | 45.112 | 48.097 | 21.295 | 23.401 |
Cash | 3.032 | 4.707 | 16.219 | 2.228 | 3.329 |
Inversiones a corto plazo | 38.015 | 40.405 | 31.878 | 19.067 | 20.072 |
Total deudores, neto | 0.168 | 0.13 | 0.104 | 0.016 | 0.337 |
Prepaid Expenses | 0.793 | 0.084 | 0.336 | 0.318 | 0.457 |
Total Assets | 42.211 | 45.551 | 48.664 | 21.774 | 24.356 |
Property/Plant/Equipment, Total - Net | 0.1 | 0.112 | 0.127 | 0.145 | 0.161 |
Property/Plant/Equipment, Total - Gross | 0.162 | 0.179 | 0.187 | 0.199 | 0.209 |
Accumulated Depreciation, Total | -0.062 | -0.067 | -0.06 | -0.054 | -0.048 |
Total Current Liabilities | 1.434 | 1.524 | 1.624 | 1.44 | 1.178 |
Accounts Payable | 0.433 | 0.509 | 0.699 | 0.239 | 0.689 |
Accrued Expenses | 0.995 | 1.011 | 0.921 | 1.196 | 0.483 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.006 | 0.004 | 0.004 | 0.005 | 0.006 |
Total Liabilities | 1.443 | 1.527 | 1.628 | 1.456 | 1.211 |
Total Long Term Debt | 0.009 | 0.003 | 0.004 | 0.005 | 0.005 |
Capital Lease Obligations | 0.009 | 0.003 | 0.004 | 0.005 | 0.005 |
Other Liabilities, Total | 0 | 0 | 0.011 | 0.028 | |
Total Equity | 40.768 | 44.024 | 47.036 | 20.318 | 23.145 |
Common Stock | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 126.884 | 126.576 | 126.296 | 96.126 | 95.68 |
Retained Earnings (Accumulated Deficit) | -86.009 | -82.501 | -79.255 | -75.805 | -72.531 |
Other Equity, Total | -0.107 | -0.051 | -0.005 | -0.003 | -0.004 |
Total Liabilities & Shareholders’ Equity | 42.211 | 45.551 | 48.664 | 21.774 | 24.356 |
Total Common Shares Outstanding | 26.4431 | 26.4431 | 26.4392 | 18.7862 | 18.7862 |
Accounts Receivable - Trade, Net | 0.166 | 0.13 | |||
Other Current Assets, Total | 0.103 | 0.113 |
- Anual
- Trimestral
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Ingresos netos/Línea de salida | -13.592 | -12.292 | -10.649 | -5.734 | -4.26 |
Efectivo de actividades de explotación | -12.252 | -9.185 | -9.102 | -5.696 | -3.9 |
Efectivo de actividades de explotación | 0.024 | 0.021 | 0.021 | 0.015 | 0.004 |
Partidas no monetarias | 1.777 | 1.891 | 1.139 | 0.659 | 0.4 |
Intereses pagados en efectivo | 0.002 | 0.002 | |||
Cambios en el capital circulante | -0.461 | 1.195 | 0.387 | -0.636 | -0.044 |
Efectivo de actividades de inversión | -20.537 | -16.134 | -3.908 | -0.05 | -0.022 |
Gastos de capital | -0.022 | -0.047 | -0.002 | -0.05 | -0.022 |
Efectivo procedente de actividades de financiación | 30.087 | 28.845 | 0.07 | 21.216 | 3.539 |
Emisión (retiro) de acciones, neto | 30.093 | 28.85 | 0.075 | 21.216 | 3.539 |
Efectos del cambio de divisas | |||||
Variación neta de la tesorería | -2.702 | 3.526 | -12.94 | 15.47 | -0.383 |
Cash Taxes Paid | 0.028 | 0.036 | 0.026 | ||
Otras partidas de flujo de caja de inversión, total | -20.515 | -16.087 | -3.906 | ||
Emisión (amortización) de deuda, neta | -0.006 | -0.005 | -0.005 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -3.508 | -13.592 | -10.346 | -6.896 | -3.622 |
Cash From Operating Activities | -3.888 | -12.252 | -9.448 | -6.402 | -4.313 |
Cash From Operating Activities | 0.006 | 0.024 | 0.018 | 0.012 | 0.006 |
Non-Cash Items | 0.443 | 1.777 | 1.354 | 1.023 | 0.551 |
Changes in Working Capital | -0.829 | -0.461 | -0.474 | -0.541 | -1.248 |
Cash From Investing Activities | 2.214 | -20.537 | -11.848 | 0.98 | -0.009 |
Capital Expenditures | 0 | -0.022 | -0.015 | -0.013 | -0.009 |
Other Investing Cash Flow Items, Total | 2.214 | -20.515 | -11.833 | 0.993 | 0 |
Cash From Financing Activities | -0.001 | 30.087 | 30.106 | 0.241 | 0.242 |
Issuance (Retirement) of Stock, Net | 0 | 30.093 | 30.111 | 0.244 | 0.244 |
Issuance (Retirement) of Debt, Net | -0.001 | -0.006 | -0.005 | -0.003 | -0.002 |
Net Change in Cash | -1.675 | -2.702 | 8.81 | -5.181 | -4.08 |
Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
---|---|---|---|---|---|---|
EQT Partners AB | Private Equity | 10.8 | 2855847 | 304827 | 2022-07-08 | LOW |
Trill AB,LLC. | Corporation | 9.6472 | 2551020 | 2551020 | 2021-09-28 | |
Jacinto (Richard II) | Individual Investor | 9.4543 | 2500000 | 850947 | 2022-12-31 | LOW |
Lytton (Laurence W) | Individual Investor | 4.0539 | 1071970 | -308296 | 2021-12-31 | MED |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.961 | 782989 | 349 | 2022-12-31 | LOW |
Giuffre (Randall Michael) | Individual Investor | 1.4983 | 396184 | 35130 | 2023-01-03 | LOW |
Omega Advisors, Inc. | Investment Advisor | 1.1345 | 300000 | 100000 | 2021-12-31 | LOW |
Jacob Asset Management of New York, LLC | Investment Advisor | 0.8839 | 233730 | -4770 | 2022-12-31 | LOW |
Pilnik (Richard D) | Individual Investor | 0.7937 | 209882 | 55555 | 2023-01-03 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.6991 | 184870 | -349 | 2022-12-31 | LOW |
Lynch (Timothy Patrick) | Individual Investor | 0.3792 | 100259 | -100000 | 2022-12-31 | LOW |
Burroughs (Amy Louise) | Individual Investor | 0.2772 | 73288 | 17156 | 2023-01-03 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.2723 | 72012 | 2814 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.252 | 66629 | 0 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.2496 | 65997 | 1067 | 2022-12-31 | LOW |
Pauls (Dietrich John) | Individual Investor | 0.211 | 55804 | 20000 | 2022-11-16 | |
Morgan Stanley & Co. LLC | Research Firm | 0.1672 | 44201 | 2194 | 2022-12-31 | MED |
Alcorn Harry W Jr | Individual Investor | 0.1663 | 43981 | 399 | 2022-03-22 | MED |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.1612 | 42634 | 0 | 2022-12-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 0.1483 | 39216 | 4304 | 2022-12-31 | HIGH |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group500K+
Traders
92K+
Clientes activos mensualmente
$53M+
Volumen mensual de inversión
$30M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
DiaMedica Therapeutics Inc. Company profile
Sobre DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc. es una empresa biofarmacéutica en fase clínica. La empresa se centra en el desarrollo de tratamientos para enfermedades neurológicas y renales, como el ictus isquémico agudo (AIS) y la enfermedad renal crónica (ERC). El producto principal de la empresa, DM199, imita el comportamiento de las proteínas humanas KLK1 de origen natural para preservar y restaurar la circulación del tejido dañado por el ictus y mejorar la función renal general. La KLK1 es una proteína de serina que se produce principalmente en los riñones, el páncreas y las glándulas salivales. La terapia con DM199 tiene el potencial de mejorar la circulación y la función general de los sistemas críticos, así como de reducir la inflamación y el estrés oxidativo. La empresa también cuenta con otras líneas de productos para la nefropatía por IgA y para los afroamericanos con enfermedad renal crónica.
Industry: | Bio Therapeutic Drugs |
301 Carlson Parkway
Suite 210
MINNEAPOLIS
MINNESOTA 55305
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com